BLA 021597 · Emd Serono
Zorbtive
Somatropin Recombinant · Injection
OrphanLast checked: Nov 20, 2026Latest source record: Dec 1, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Dec 1, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
278
105 Phase 3, 12 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- ZORBTIVE · SOMATROPIN RECOMBINANT 5MG/VIAL · INJECTABLE, INJECTION · Discontinued
- ZORBTIVE · SOMATROPIN RECOMBINANT 6MG/VIAL · INJECTABLE, INJECTION · Discontinued
- ZORBTIVE · SOMATROPIN RECOMBINANT 4MG/VIAL · INJECTABLE, INJECTION · Discontinued
- ZORBTIVE · SOMATROPIN RECOMBINANT 8.8MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin Recombinant" as an intervention, any sponsor and status, largest first.
- Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03290235 · 1,500 participants (planned) · Start Mar 1, 2017 · Primary completion Oct 2020
Drug: PEG-somatropin · For: Growth Retardation
Sites: Wuhan, China
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03249480 · 900 participants (planned) · Start Jan 2015 · Primary completion Aug 2017
Drug: PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 28 sites in all
- Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency ChildrenStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02314676 · 900 participants (planned) · Start Nov 2014 · Primary completion Jul 2017
Drug: PEG-somatropin · For: Dwarfism, Pituitary
Sites: Wuhu, China; Hangzhou, China
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02908958 · 900 participants (planned) · Start Nov 2014 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Wuhu, China; Xiamen, China · 22 sites in all
- The Effect of Somatropin Treatment in Adult Patients on Chronic DialysisPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00503698 · 712 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: somatropin; placebo · For: Chronic Kidney Disease; End-Stage Renal Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Madison, Alabama · 381 sites in all
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
- Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone DeficiencyPivotal-lookingStatus unknown
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT02976675 · 600 participants (planned) · Start Jan 2015 · Primary completion Jun 2017
Drug: PEG-somatropin; PEG-somatropin · For: Growth Hormone Deficiency
Sites: Hefei, China; Lu'an, China; Lanzhou, China · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Emd Serono
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.